Abattis Bioceuticals Corp (ATT) Director Sells C$33,000.00 in Stock

Abattis Bioceuticals Corp (CNSX:ATT) Director Shuang Xie sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of C$0.66, for a total value of C$33,000.00.

Shuang Xie also recently made the following trade(s):

  • On Tuesday, November 28th, Shuang Xie sold 10,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.32, for a total value of C$3,200.00.
  • On Thursday, November 23rd, Shuang Xie sold 50,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.23, for a total value of C$11,500.00.

Shares of Abattis Bioceuticals Corp (CNSX ATT) traded down C$0.04 during midday trading on Thursday, hitting C$0.48. The stock had a trading volume of 7,070,000 shares, compared to its average volume of 2,120,000. Abattis Bioceuticals Corp has a one year low of C$0.05 and a one year high of C$0.58.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/21/abattis-bioceuticals-corp-att-director-sells-c33000-00-in-stock.html.

Abattis Bioceuticals Company Profile

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets.

What are top analysts saying about Abattis Bioceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abattis Bioceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit